Abstract

PurposeThis study aimed to establish and validate a radiomics nomogram based on dynamic contrast-enhanced (DCE)-MRI for predicting axillary lymph node (ALN) metastasis in breast cancer.MethodThis retrospective study included 296 patients with breast cancer who underwent DCE-MRI examinations between July 2017 and June 2018. A total of 396 radiomics features were extracted from primary tumor. In addition, the least absolute shrinkage and selection operator (LASSO) algorithm was used to select the features. Radiomics signature and independent risk factors were incorporated to build a radiomics nomogram model. Calibration and receiver operator characteristic (ROC) curves were used to confirm the performance of the nomogram in the training and validation sets. The clinical usefulness of the nomogram was evaluated by decision curve analysis (DCA).ResultsThe radiomics signature consisted of three ALN-status-related features, and the nomogram model included the radiomics signature and the MR-reported lymph node (LN) status. The model showed good calibration and discrimination with areas under the ROC curve (AUC) of 0.92 [95% confidence interval (CI), 0.87–0.97] in the training set and 0.90 (95% CI, 0.85–0.95) in the validation set. In the MR-reported LN-negative (cN0) subgroup, the nomogram model also exhibited favorable discriminatory ability (AUC, 0.79; 95% CI, 0.70–0.87). DCA findings indicated that the nomogram model was clinically useful.ConclusionsThe MRI-based radiomics nomogram model could be used to preoperatively predict the ALN metastasis of breast cancer.

Highlights

  • Breast cancer is a malignant tumor that endangers women’s health and quality of life

  • This study aimed to develop and validate a radiomics nomogram model based on dynamic contrast-enhanced (DCE)-MRI and clinical risk factors to determine its potential in predicting Axillary lymph node (ALN) metastasis in patients with breast cancer

  • A radiomics nomogram model based on MRI was developed to predict the pretreatment of ALN metastasis in breast cancer and was validated using an independent dataset

Read more

Summary

Introduction

Breast cancer is a malignant tumor that endangers women’s health and quality of life. Axillary lymph node (ALN) is the first station of breast lymphatic drainage, which collects approximately 75% of breast lymph. ALN is the most metastasized site of breast cancer. ALN status is an important factor affecting the treatment of patients with breast cancer and is assess by the gold. Axillary Lymph Node Metastasis Prediction standards ALN dissection and sentinel lymph node (LN) biopsy. ALN dissection is invasive and has many complications, such as lymphedema, and sentinel LN biopsy is invasive [1]. A non-invasive prediction tool for preoperative LN status is needed

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call